Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy - PubMed (original) (raw)
. 2018 Jan;136(2):403-411.
doi: 10.1007/s11060-017-2668-5. Epub 2017 Nov 16.
Affiliations
- PMID: 29143923
- DOI: 10.1007/s11060-017-2668-5
Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy
Alexander J Lin et al. J Neurooncol. 2018 Jan.
Abstract
Prolonged severe lymphopenia has been shown to persist beyond a year in glioma patients after radiation therapy (RT) with concurrent and adjuvant chemotherapy. This study examines the differential impact of concurrent versus adjuvant chemotherapy on lymphopenia after RT. WHO grade II-III glioma patients who received RT with concurrent and/or adjuvant chemotherapy from 2007 to 2016 were retrospectively analyzed. Concurrent chemotherapy was temozolomide (TMZ), and adjuvant chemotherapy was either TMZ or procarbazine/lomustine/vincristine (PCV). Absolute lymphocyte count (ALC) was analyzed at baseline, 1.5, 3, 6, and 12 months after the start of RT. Univariable and multivariable logistic regression were used to identify the clinical variables in predicting acute or late lymphopenia. There were 151 patients with evaluable ALC: 91 received concurrent and adjuvant TMZ (CRT + ADJ), 32 received only concurrent TMZ (CRT), and 28 received only adjuvant TMZ or PCV (ADJ). There were 9 (10%) versus 6 (19%) versus 0 (0%) cases of grade 3 lymphopenia (ALC < 500/mm3) at 6 weeks and 4 (6%) versus 0 (0%) versus 3 (17%) cases at 12 months in CRT + ADJ, CRT and ADJ groups, respectively. On multivariable analyses, concurrent chemotherapy (odds ratio [OR] 72.3, p < 0.001), female sex (OR 10.8, p < 0.001), and older age (OR 1.06, p = 0.002) were the most significant predictors for any grade ≥ 1 lymphopenia (ALC < 1000/mm3) at 1.5 months. Older age (OR 1.08, p = 0.02) and duration of adjuvant chemotherapy (OR 1.19, p = 0.003) were significantly associated with grade ≥ 1 lymphopenia at 12 months. Thus, concurrent chemotherapy appears as the dominant contributor to the severity of acute lymphopenia after RT in WHO grade II-III glioma patients, and duration of adjuvant chemotherapy appears as the key factor to prolonged lymphopenia.
Keywords: Adjuvant chemotherapy; Concurrent chemotherapy; Glioma; Lymphopenia; Radiation therapy.
Similar articles
- Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR, Kim AH, Dunn G, Simpson JR, Robinson CG. Huang J, et al. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1000-1007. doi: 10.1016/j.ijrobp.2015.04.005. Epub 2015 Apr 8. Int J Radiat Oncol Biol Phys. 2015. PMID: 26025775 - Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Ishikawa E, Yamamoto T, Sakamoto N, Nakai K, Akutsu H, Tsuboi K, Takano S, Matsumura A. Ishikawa E, et al. Neurol Med Chir (Tokyo). 2010;50(8):638-44. doi: 10.2176/nmc.50.638. Neurol Med Chir (Tokyo). 2010. PMID: 20805645 - Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
van den Bent MJ. van den Bent MJ. Neuro Oncol. 2014 Dec;16(12):1570-4. doi: 10.1093/neuonc/nou297. Epub 2014 Oct 29. Neuro Oncol. 2014. PMID: 25355680 Free PMC article. Review. - Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Wang J, Wang Y, He Y, Guan H, He L, Mu X, Peng X. Wang J, et al. Trials. 2019 Nov 21;20(1):641. doi: 10.1186/s13063-019-3741-5. Trials. 2019. PMID: 31752981 Free PMC article.
Cited by
- Immunotherapy Against Gliomas: is the Breakthrough Near?
Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM. Lukas RV, et al. Drugs. 2019 Nov;79(17):1839-1848. doi: 10.1007/s40265-019-01203-z. Drugs. 2019. PMID: 31598900 Free PMC article. Review. - Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
Ortiz R, Perazzoli G, Cabeza L, Jiménez-Luna C, Luque R, Prados J, Melguizo C. Ortiz R, et al. Curr Neuropharmacol. 2021;19(4):513-537. doi: 10.2174/1570159X18666200626204005. Curr Neuropharmacol. 2021. PMID: 32589560 Free PMC article. Review. - Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Hotchkiss KM, Sampson JH. Hotchkiss KM, et al. J Neurooncol. 2021 Jan;151(1):55-62. doi: 10.1007/s11060-020-03598-2. Epub 2020 Aug 19. J Neurooncol. 2021. PMID: 32813186 Free PMC article. Review. - Etiology and prognosis of acute respiratory failure in patients with primary malignant brain tumors admitted to the intensive care unit.
Decavèle M, Rivals I, Marois C, Cantier M, Weiss N, Lemasle L, Prodanovic H, Hoang-Xuan K, Idbaih A, Similowski T, Demoule A. Decavèle M, et al. J Neurooncol. 2019 Mar;142(1):139-148. doi: 10.1007/s11060-018-03074-y. Epub 2018 Dec 7. J Neurooncol. 2019. PMID: 30536197 - Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma.
Luo H, Tao C, Long X, Zhu X, Huang K. Luo H, et al. Bioengineered. 2021 Dec;12(1):7765-7779. doi: 10.1080/21655979.2021.1985340. Bioengineered. 2021. PMID: 34617871 Free PMC article.
References
- Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
- Cancer Invest. 2013 Feb;31(2):140-4 - PubMed
- J Clin Oncol. 2013 Jan 20;31(3):337-43 - PubMed
- Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
- Neuro Oncol. 2017 Aug 1;19(8):1119-1126 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials